Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Amarin Corp Ads (NQ: AMRN)
18.80 USD  +0.72 (+3.98%)
Streaming Delayed Price  /  Updated: 2:25 PM EDT, Jun 17, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 4,227,991
Open 18.10
Bid (Size) 18.79 (13)
Ask (Size) 18.80 (1)
Prev. Close 18.08
Today's Range 17.77 - 18.85
52wk Range 2.350 - 23.33
Shares Outstanding 293,584,140
Dividend Yield N/A
Performance
YTD
+44.50%
+44.50%
1 Month
+5.68%
+5.68%
3 Month
-2.59%
-2.59%
6 Month
+20.90%
+20.90%
1 Year
+485.67%
+485.67%
Top News
More News
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual Americ
Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that three Amarin-supported posters will be presented at the American... Read More
from GlobeNewswire News Releases
Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero,... Read More
from GlobeNewswire News Releases
More News
Read More
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
from GlobeNewswire News Releases
Amarin to Present at the Jefferies 2019 Healthcare Conference
from GlobeNewswire News Releases
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
from GlobeNewswire News Releases
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting
from GlobeNewswire News Releases
Analysts Predict 32% Gains Ahead For The Holdings of BIB
category ETFs
from ETF Channel
3 Top Mid-Cap Stocks to Buy Right Now
category AMRN , RGLD , AAXN , and 1 more.
from Motley Fool
Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation
category Vascepa , Biotech , Market News , and 5 more.
from Benzinga
Why Cypress Semiconductor, Amarin, and Heico Jumped Today
category AMRN , HEI , Market News , and 1 more.
from Motley Fool
This Biotech Stock Rocketed Near A Buy Point On Speedy Drug Review
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.